Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Major Japanese medical device maker Terumo obtained conditional approval for its cell-based heart failure therapy, HeartSheet, the first such approval given in Japan since a new “regenerative medicine” category was created under the revised pharmaceutical affairs law. HeartSheet, autologous skeletal…
To read the full story
Related Article
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Drug Pricing Organization to Price JCR’s Cell Therapy Temcell
October 1, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





